RU2010150754A - АНТИТЕЛА ПРОТИВ PirB - Google Patents

АНТИТЕЛА ПРОТИВ PirB Download PDF

Info

Publication number
RU2010150754A
RU2010150754A RU2010150754/10A RU2010150754A RU2010150754A RU 2010150754 A RU2010150754 A RU 2010150754A RU 2010150754/10 A RU2010150754/10 A RU 2010150754/10A RU 2010150754 A RU2010150754 A RU 2010150754A RU 2010150754 A RU2010150754 A RU 2010150754A
Authority
RU
Russia
Prior art keywords
antibody
pirb
lilrb
seq
heavy chain
Prior art date
Application number
RU2010150754/10A
Other languages
English (en)
Russian (ru)
Inventor
Джасвиндер ЭТАВАЛ (US)
Джасвиндер ЭТАВАЛ
Марк ТЕССЬЕ-ЛАВИНЬ (US)
Марк ТЕССЬЕ-ЛАВИНЬ
Янь У (US)
Янь У
Original Assignee
Дженентек, Инк. (Us)
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Application filed by Дженентек, Инк. (Us), Дженентек, Инк. filed Critical Дженентек, Инк. (Us)
Publication of RU2010150754A publication Critical patent/RU2010150754A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2010150754/10A 2008-05-13 2009-05-13 АНТИТЕЛА ПРОТИВ PirB RU2010150754A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US61/052,949 2008-05-13
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/208,883 2008-09-11
US12/316,130 2008-12-09

Publications (1)

Publication Number Publication Date
RU2010150754A true RU2010150754A (ru) 2012-06-20

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010150754/10A RU2010150754A (ru) 2008-05-13 2009-05-13 АНТИТЕЛА ПРОТИВ PirB

Country Status (15)

Country Link
EP (1) EP2291405A1 (zh)
JP (1) JP2011523359A (zh)
KR (1) KR20110011676A (zh)
CN (1) CN102089327A (zh)
AR (1) AR071777A1 (zh)
AU (1) AU2009246443A1 (zh)
BR (1) BRPI0912769A2 (zh)
CA (1) CA2723430A1 (zh)
IL (1) IL209129A0 (zh)
MX (1) MX2010012299A (zh)
PE (1) PE20091969A1 (zh)
RU (1) RU2010150754A (zh)
TW (1) TW200950808A (zh)
WO (1) WO2009140361A1 (zh)
ZA (1) ZA201007976B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
ES2870717T3 (es) * 2012-04-17 2021-10-27 Mayo Found Medical Education & Res Anticuerpos humanos y secuencias de unión específicas del mismo para su uso en accidente cerebrovascular e isquemia y condiciones isquémicas
CN103130898B (zh) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用
AU2018389111A1 (en) 2017-12-22 2020-06-18 Jounce Therapeutics, Inc. Antibodies to LILRB2
JP7411627B2 (ja) 2018-07-09 2024-01-11 ファイヴ プライム セラピューティクス インク Ｉｌｔ４と結合する抗体
CN109439661B (zh) * 2018-10-22 2020-10-23 西安医学院 抑制pirB表达的短发卡shRNA、慢病毒及其应用
CN116589581A (zh) 2020-05-01 2023-08-15 恩格姆生物制药公司 Ilt结合剂和其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453540A4 (en) * 2001-11-14 2005-06-01 Immunex Corp MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
EP1981522B1 (en) * 2006-01-23 2012-09-12 President and Fellows of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Also Published As

Publication number Publication date
MX2010012299A (es) 2010-12-06
CN102089327A (zh) 2011-06-08
PE20091969A1 (es) 2010-01-15
KR20110011676A (ko) 2011-02-08
EP2291405A1 (en) 2011-03-09
BRPI0912769A2 (pt) 2015-10-13
ZA201007976B (en) 2012-02-29
JP2011523359A (ja) 2011-08-11
AR071777A1 (es) 2010-07-14
AU2009246443A1 (en) 2009-11-19
CA2723430A1 (en) 2009-11-19
WO2009140361A1 (en) 2009-11-19
TW200950808A (en) 2009-12-16
IL209129A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
RU2010150754A (ru) АНТИТЕЛА ПРОТИВ PirB
RU2010150348A (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применение
RU2010139886A (ru) Моноклональные антитела против белка rgm а и их применение
PH12011502389A1 (en) Monoclonal antibody
RU2474588C2 (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
ECSP055939A (es) Inmunizacion activa para generar anticuerpos para beta-a soluble
MX2009013503A (es) Anticuerpo monoclonal anti-amiloide-beta.
WO2009052081A4 (en) Antibodies that bind il-4 and/or il-13 and their uses
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
HRP20161069T1 (hr) Molekule antitijela koje vezuju il-17a i il-17f
JP2010526028A5 (zh)
JP2011523359A5 (zh)
RU2008129080A (ru) Средства и способы лечения опухолевых заболеваний
RU2014109039A (ru) Биспецифические антигенсвязывающие молекулы
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
RU2009118621A (ru) Агонистические антитела против notch3 и их применение для лечения ntch3-ассоциированных заболеваний
JP2014503189A5 (zh)
JP2007522096A5 (zh)
CA2501984A1 (en) Erythropoietin receptor binding antibodies
RU2013141078A (ru) Одновалентные антигенсвязывающие белки
MX2009002418A (es) Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
RU2009133789A (ru) Способы лечения глазных болезней
RU2015118180A (ru) Антитела к бета-амилоиду
JP2015517502A5 (zh)
RU2020133229A (ru) Антитела к klk5 и способы применения

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20130802